Ocular melanoma, also known as uveal or eye melanoma, is a rare but aggressive cancer that develops in the eye’s pigment cells. Because it often progresses silently, many patients are not diagnosed until later stages when treatment options are more limited.

The Eye Immunomelanoma Assay evaluates immune and prometastatic biomarker activity specific to ocular melanoma. By detecting these molecular changes early, the assay provides clinicians with critical insights for risk assessment, treatment guidance, and recurrence monitoring.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Eye Immunomelanoma Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Risk Identification

Detects immune and molecular activity linked to eye melanoma before advanced progression.

Precision Oncology Guidance

Supports immunotherapy and targeted therapy planning with molecular evidence.

Monitoring Capability

Tracks biomarker changes during treatment and follow-up care.

Complementary Evidence

Adds molecular context to imaging and ophthalmological exams.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Eye Immunomelanoma Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and ocular melanoma progression:

  • Immune checkpoint proteins (PD-L1, CTLA-4 pathways)

  • Tumor-promoting cytokines and inflammatory signals (IL-6, IL-8, TNF-α)

  • Angiogenesis factors (VEGF, FGF) driving ocular tumor growth

  • Tumor microenvironment and prometastatic proteins

  • Oxidative and metabolic stress markers unique to ocular tissue

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers through Persona Biomed’s secure portal.

02

Sample Collection

Blood draw at a certified clinic or via mobile phlebotomy.

03

Laboratory Analysis

Assays evaluate immunocarcinogenic and prometastatic biomarker patterns specific to ocular melanoma.

04

Results Delivery

Detailed physician-ready report delivered in the portal, with AI-powered summaries for patient understanding.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with a family history or genetic predisposition to ocular melanoma.

  • Individuals with suspicious ocular lesions or abnormal ophthalmic imaging.

  • Patients undergoing treatment for ocular melanoma needing molecular monitoring.

  • Survivors requiring long-term recurrence surveillance.

Register Now for
Eye Immunomelanoma Assay

Register now for the Eye Immunomelanoma Assay to uncover hidden molecular signals of ocular melanoma and guide proactive, precision treatment.

Register now